John Sundy

Director at Neutrolis

Capital raised by Neutrolis

$4.5M+$3.5M latest round

2 Form D filings · first filed Feb 2025 · Cambridge, MA

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 3
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

NeutrolisBiotech · Cambridge, MAsince Feb 2025

Director

Listed on Neutrolis's Form D filings

Company filings

via EDGAR · Form D for Neutrolis2

DateCompanyFormAmountRole on filing

Jun 20, 2025NeutrolisForm D+$3.5M—

Form DJun 20, 2025 · Neutrolis+$3.5Mnot a signer

Feb 28, 2025NeutrolisForm D+$965K—

Form DFeb 28, 2025 · Neutrolis+$965Knot a signer

Overview

Last filing Jun 20, 2025

John Sundy is on file as Director at Neutrolis in Cambridge, MA. Neutrolis has 2 Form D filings on record, $4.5M raised in total.

Teammates

Neutrolis · 2

Anthony AiudiChief Executive Officer of the IssuerSigner Toby FoxChief Executive Officer of the IssuerSigner

Products

Neutrolis · 1

exDNASE™ platformBiopharmaceuticals

The exDNASE™ platform is Neutrolis’s proprietary technology designed to engineer enzymes specifically for the degradation of Neutrophil Extracellular Traps (NETs). This platform is pivotal in developing therapies that can mitigate the damaging effects of overactive neutrophils in autoimmune and inflammatory diseases.